每經AI快(kuai)訊，有投資者在投資者互動(dong)平臺(tai)提問(wen)：請(qing)問(wen)公司(si)新產(chan)品推(tui)廣為何多(duo)年見不(bu)到成(cheng)效？巨額管理費用中，推(tui)廣費用能(neng)不(bu)能(neng)占到百萬(wan)分之一？謝謝。

萬潤股份（002643.SZ）3月8日在(zai)投資(zi)者(zhe)互動平(ping)臺表示，公(gong)(gong)(gong)司(si)(si)(si)主要從事電子(zi)信(xin)息(xi)(xi)材(cai)(cai)(cai)料(liao)產(chan)(chan)(chan)(chan)(chan)業(ye)、環(huan)保材(cai)(cai)(cai)料(liao)產(chan)(chan)(chan)(chan)(chan)業(ye)和大健康產(chan)(chan)(chan)(chan)(chan)業(ye)三(san)個(ge)(ge)(ge)領(ling)(ling)(ling)(ling)(ling)域(yu)(yu)(yu)產(chan)(chan)(chan)(chan)(chan)品(pin)(pin)的(de)(de)(de)研發(fa)、生產(chan)(chan)(chan)(chan)(chan)和銷售。公(gong)(gong)(gong)司(si)(si)(si)自成立以(yi)來(lai)一直(zhi)專注于(yu)(yu)化(hua)學(xue)合成技(ji)術(shu)的(de)(de)(de)研發(fa)與(yu)產(chan)(chan)(chan)(chan)(chan)業(ye)化(hua)應用(yong)，依(yi)托于(yu)(yu)強大的(de)(de)(de)研發(fa)團(tuan)隊和自主創新能(neng)力，公(gong)(gong)(gong)司(si)(si)(si)年(nian)均(jun)開發(fa)產(chan)(chan)(chan)(chan)(chan)品(pin)(pin)數百種(zhong)(zhong)，現擁有超過(guo)6,000種(zhong)(zhong)化(hua)合物(wu)的(de)(de)(de)生產(chan)(chan)(chan)(chan)(chan)技(ji)術(shu)，其(qi)中2,000余種(zhong)(zhong)產(chan)(chan)(chan)(chan)(chan)品(pin)(pin)已投入市(shi)場，獲(huo)得國內(nei)外發(fa)明專利五百余項。在(zai)電子(zi)信(xin)息(xi)(xi)材(cai)(cai)(cai)料(liao)產(chan)(chan)(chan)(chan)(chan)業(ye)與(yu)環(huan)保材(cai)(cai)(cai)料(liao)產(chan)(chan)(chan)(chan)(chan)業(ye)方(fang)面，公(gong)(gong)(gong)司(si)(si)(si)依(yi)托于(yu)(yu)在(zai)化(hua)學(xue)合成領(ling)(ling)(ling)(ling)(ling)域(yu)(yu)(yu)的(de)(de)(de)科(ke)技(ji)創新與(yu)技(ji)術(shu)積累及延伸，先(xian)(xian)后涉足(zu)了液晶材(cai)(cai)(cai)料(liao)、OLED材(cai)(cai)(cai)料(liao)、沸石系列(lie)環(huan)保材(cai)(cai)(cai)料(liao)等多個(ge)(ge)(ge)領(ling)(ling)(ling)(ling)(ling)域(yu)(yu)(yu)，并(bing)已在(zai)上述領(ling)(ling)(ling)(ling)(ling)域(yu)(yu)(yu)取(qu)得了業(ye)內(nei)領(ling)(ling)(ling)(ling)(ling)先(xian)(xian)地(di)位；近年(nian)來(lai)公(gong)(gong)(gong)司(si)(si)(si)在(zai)聚酰亞胺材(cai)(cai)(cai)料(liao)、半導體制(zhi)(zhi)造(zao)材(cai)(cai)(cai)料(liao)、新能(neng)源材(cai)(cai)(cai)料(liao)等多個(ge)(ge)(ge)領(ling)(ling)(ling)(ling)(ling)域(yu)(yu)(yu)積極布局。在(zai)大健康產(chan)(chan)(chan)(chan)(chan)業(ye)方(fang)面，公(gong)(gong)(gong)司(si)(si)(si)經過(guo)多年(nian)對醫(yi)藥市(shi)場的(de)(de)(de)開拓和醫(yi)藥技(ji)術(shu)的(de)(de)(de)儲備，先(xian)(xian)后涉足(zu)醫(yi)藥中間體、成藥制(zhi)(zhi)劑(ji)、原料(liao)藥、生命科(ke)學(xue)、體外診(zhen)斷(duan)等多個(ge)(ge)(ge)領(ling)(ling)(ling)(ling)(ling)域(yu)(yu)(yu)。未(wei)來(lai)公(gong)(gong)(gong)司(si)(si)(si)將在(zai)鞏固現有領(ling)(ling)(ling)(ling)(ling)域(yu)(yu)(yu)優勢地(di)位的(de)(de)(de)同時，進一步提高新產(chan)(chan)(chan)(chan)(chan)品(pin)(pin)研發(fa)與(yu)產(chan)(chan)(chan)(chan)(chan)業(ye)化(hua)效率，不(bu)斷(duan)豐富公(gong)(gong)(gong)司(si)(si)(si)產(chan)(chan)(chan)(chan)(chan)品(pin)(pin)種(zhong)(zhong)類(lei)，提升(sheng)公(gong)(gong)(gong)司(si)(si)(si)核心競爭力，力爭將公(gong)(gong)(gong)司(si)(si)(si)打(da)造(zao)成為世界先(xian)(xian)進化(hua)學(xue)材(cai)(cai)(cai)料(liao)制(zhi)(zhi)造(zao)者(zhe)，公(gong)(gong)(gong)司(si)(si)(si)經營層對公(gong)(gong)(gong)司(si)(si)(si)未(wei)來(lai)發(fa)展充(chong)滿信(xin)心。近年(nian)來(lai)隨(sui)著公(gong)(gong)(gong)司(si)(si)(si)業(ye)務增加(jia)公(gong)(gong)(gong)司(si)(si)(si)管(guan)理(li)費(fei)(fei)用(yong)隨(sui)之增長。公(gong)(gong)(gong)司(si)(si)(si)銷售費(fei)(fei)用(yong)與(yu)管(guan)理(li)費(fei)(fei)用(yong)情況詳見公(gong)(gong)(gong)司(si)(si)(si)的(de)(de)(de)定(ding)期報告。

(記者 王瀚黎)

免責聲(sheng)明(ming)：本文(wen)內容(rong)與數據(ju)僅供參考，不構成(cheng)投資建議，使用前核(he)實。據(ju)此(ci)操作，風險自擔。